Carvana raises 2024 earnings guidance after topping Wall Street’s Q3 expectations

Carvana raises 2024 earnings guidance after topping Wall Street’s Q3 expectations


A Carvana sign and signature vending machine in Tempe, Arizona.

Michael Wayland | CNBC

Carvana on Wednesday raised its 2024 earnings guidance after the online used-car retailer significantly topped Wall Street’s third-quarter expectations.

Here’s how the company performed in the third quarter, compared with average estimates compiled by LSEG:

  • Earnings per share: 64 cents vs. 25 cents expected
  • Revenue: $3.65 billion vs. $3.45 billion expected

The company’s stock rose roughly 20% in after-hours trading Wednesday.

For 2024 guidance, Carvana said its adjusted earnings before interest, taxes, depreciation and amortization would be “significantly above the high end” of its previous target of $1 billion to $1.2 billion. The company reported $339 million in adjusted EBITDA last year.

Carvana’s new guidance signals expectations for a strong end of the year. The company said it expects a sequential increase in retail vehicle sales during the fourth quarter compared with the prior three months, which totaled 108,651 vehicles.

For the third quarter, the company’s net income was $148 million, down from $741 million a year earlier that was inflated by a gain on debt reduction. Adjusted EBITDA was $429 million and adjusted EBITDA margin was 11.7%, both topping company records achieved during the second quarter.

The company’s third-quarter 2023 results included adjusted EBITDA of $148 million and revenue of $2.77 billion.

Shares of Carvana are up roughly 300% this year as the company restructured operations and cut costs following Wall Street concerns of bankruptcy for the company in late 2022.

Carvana stock closed Wednesday at $207.31 per share, down less than 1%. Shares hit a new 52-week high earlier in the day of $213.98 per share.

Don’t miss these insights from CNBC PRO



Source

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More
Disney embarks on new chapter as Josh D’Amaro takes over as CEO
Business

Disney embarks on new chapter as Josh D’Amaro takes over as CEO

Larissa Manoela and Josh D’Amaro, Chairperson of Walt Disney Parks and Resorts, wave to the audience after Panel Disney Experiences during Day 2 of the D23 Brazil: A Disney Experience at Transamerica Expo Center on November 09, 2024 in Sao Paulo, Brazil. Ricardo Moreira | Getty Images Disney is turning the page on a new […]

Read More